Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000, Australia
Signatory: Julian Babarczy, Chairman (Date: July 28, 2026)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate action rather than a financial results statement.
Material Changes
Corporate Action: The company submitted an "Application for quotation of securities" (Exhibit 99.1) for the ticker symbol "ATH".
Registration Statements: This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the status and approval of the application for quotation of securities (ATH) referenced in Exhibit 99.1.
- Review the specific terms of the securities being quoted, as details are not included in this summary.
- Confirm the impact of this filing on the referenced Form S-8 and Form F-3 registration statements.
- Check for subsequent filings containing financial data, as this document contains no financial metrics.